Simrat Randhawa, EVP, Head of R&D at Dianthus Therapeutics, Inc. /DE/ (DNTH), sold 393,076 shares at $38.14 ($14.8M) on 2025-11-14, disclosed to the SEC on 2025-11-14.
Scheduled sale ($14.8M) by EVP, Head of R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $35.80 | 26,166 | $937K | 6.3% |
| 2 | $35.80 | 26,166 | $937K | 6.3% |
| 3 | $37.04 | 42,765 | $1.6M | 10.7% |
| 4 | $37.04 | 42,765 | $1.6M | 10.7% |
| 5 | $37.72 | 18,576 | $701K | 4.7% |
| 6 | $37.72 | 18,576 |
| $701K |
| 4.7% |
| 7 | $38.14 | 109,031 | $4.2M | 28.2% |
| 8 | $38.14 | 109,031 | $4.2M | 28.2% |
| Total | $37.55 avg | 393,076 | $14.8M | 100% |
| Filing → |
| DNTH | SELL | 2026-03-13 | $2.8M | — | Filing → |
| DNTH | BUY | 2023-09-25 | $53K | — | Filing → |